We are developing small molecule somatic expansion inhibitors for the treatment of Huntington’s Disease and other triplet repeat expansion diseases
We are developing small molecule somatic expansion inhibitors for the treatment of Huntington’s Disease and other triplet repeat expansion diseases. Our approach has the potential to stop DNA instability and therefore slow neurodegeneration in these diseases.